DK0637236T3 - Farmaceutisk præparat og fremgangsmåde til dets fremstilling - Google Patents

Farmaceutisk præparat og fremgangsmåde til dets fremstilling

Info

Publication number
DK0637236T3
DK0637236T3 DK93908973.6T DK93908973T DK0637236T3 DK 0637236 T3 DK0637236 T3 DK 0637236T3 DK 93908973 T DK93908973 T DK 93908973T DK 0637236 T3 DK0637236 T3 DK 0637236T3
Authority
DK
Denmark
Prior art keywords
preparation
pharmaceutical composition
prepn
clodronate
dissolves
Prior art date
Application number
DK93908973.6T
Other languages
Danish (da)
English (en)
Inventor
Juhani Posti
Kirsi Katila
Pertti Rantala
Original Assignee
Leiras Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leiras Oy filed Critical Leiras Oy
Application granted granted Critical
Publication of DK0637236T3 publication Critical patent/DK0637236T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK93908973.6T 1992-04-24 1993-04-21 Farmaceutisk præparat og fremgangsmåde til dets fremstilling DK0637236T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9201299A SE501389C2 (sv) 1992-04-24 1992-04-24 Farmaceutiskt preparat och förfarande för dess framställning

Publications (1)

Publication Number Publication Date
DK0637236T3 true DK0637236T3 (da) 1997-03-17

Family

ID=20386054

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93908973.6T DK0637236T3 (da) 1992-04-24 1993-04-21 Farmaceutisk præparat og fremgangsmåde til dets fremstilling

Country Status (21)

Country Link
US (1) US5525354A (enExample)
EP (1) EP0637236B1 (enExample)
JP (1) JP3536106B2 (enExample)
AT (1) ATE143802T1 (enExample)
AU (1) AU671830B2 (enExample)
CA (1) CA2134196C (enExample)
CZ (1) CZ282871B6 (enExample)
DE (2) DE637236T1 (enExample)
DK (1) DK0637236T3 (enExample)
EE (1) EE03107B1 (enExample)
ES (1) ES2094539T3 (enExample)
FI (1) FI110667B (enExample)
GR (1) GR3022249T3 (enExample)
HK (1) HK13097A (enExample)
HU (1) HU219342B (enExample)
IL (1) IL105403A (enExample)
NO (1) NO306654B1 (enExample)
RU (1) RU2116074C1 (enExample)
SE (1) SE501389C2 (enExample)
TW (1) TW273515B (enExample)
WO (1) WO1993021907A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406714B1 (en) 1992-12-02 2002-06-18 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids
ATE128363T1 (de) * 1993-05-15 1995-10-15 Boehringer Mannheim Gmbh Tablette mit verbesserter bioverfügbarkeit enthaltend dichlormethylendiphosphonsäure als wirkstoff.
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
FI94926C (fi) * 1993-11-12 1995-11-27 Leiras Oy Menetelmä klodronaattivalmisteen valmistamiseksi
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
US20010007863A1 (en) 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
FI98343C (fi) * 1995-03-21 1997-06-10 Orion Yhtymae Oy Peroraalinen formulaatio
DE19719680A1 (de) 1997-05-09 1998-11-19 Boehringer Mannheim Gmbh Verwendung von Diphosphonsäuren zur präventiven Behandlung von Spätfolgen bei Harnblasenerweiterung oder Harnblasenersatz
JPH11137208A (ja) * 1997-11-14 1999-05-25 Nikken Chem Co Ltd 口腔内速溶性固形物及びその製造方法
EP0998932A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
EP0998933A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
DE60038097T2 (de) * 1999-02-22 2009-02-12 Merrion Research I Ltd. Feste orale dosierungsform enthaltend einen resorptionsverstärker
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
SE9901272D0 (sv) * 1999-04-09 1999-04-09 Astra Ab New improved formulation
PE20011065A1 (es) 2000-02-01 2001-11-21 Procter & Gamble Proceso para fabricar bisfosfonatos geminales
US6410520B2 (en) 2000-02-01 2002-06-25 The Procter & Gamble Company Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate
WO2002070438A2 (en) * 2001-03-01 2002-09-12 Emisphere Technologies, Inc. Compositions for delivering bisphosphonates
WO2002092616A1 (en) 2001-05-11 2002-11-21 Orasense, Ltd. Antisense permeation enhancers
US20030070584A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
AU4061702A (en) * 2001-05-15 2003-04-03 Mcneil-Ppc, Inc. Dip coating compositions containing starch or dextrin
US8309118B2 (en) * 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
US7429619B2 (en) * 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
US20080287400A1 (en) 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645459B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US20080286359A1 (en) 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645460B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US7862552B2 (en) * 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions
BRPI0710503A2 (pt) 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
DE102008022520A1 (de) * 2008-05-07 2009-11-12 Bayer Animal Health Gmbh Feste Arzneimittelformulierung mit verzögerter Freisetzung
US20090280169A1 (en) 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
WO2011120033A1 (en) 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
AU2012204213A1 (en) 2011-01-07 2013-06-13 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57171428A (en) * 1981-04-13 1982-10-22 Sankyo Co Ltd Preparation of coated solid preparation
ES2040733T3 (es) * 1986-12-20 1993-11-01 Boehringer Mannheim Gmbh Medicamentos que contienen clodronato y procedimiento para su preparacion.
EP0313845A1 (en) * 1987-09-29 1989-05-03 Warner-Lambert Company Stabilization of enteric coated dosage form
FR2629716B1 (fr) * 1988-04-07 1991-07-19 Sanofi Sa Composition pharmaceutique pour administration orale a base d'un derive d'acide diphosphonique

Also Published As

Publication number Publication date
CA2134196A1 (en) 1993-11-11
CA2134196C (en) 2004-02-10
HK13097A (en) 1997-02-14
EP0637236A1 (en) 1995-02-08
CZ282871B6 (cs) 1997-11-12
EE03107B1 (et) 1998-08-17
SE9201299L (sv) 1993-10-25
GR3022249T3 (en) 1997-04-30
ATE143802T1 (de) 1996-10-15
TW273515B (enExample) 1996-04-01
JPH07505898A (ja) 1995-06-29
NO306654B1 (no) 1999-12-06
SE501389C2 (sv) 1995-01-30
DE69305335D1 (de) 1996-11-14
AU3955093A (en) 1993-11-29
HUT74572A (en) 1997-01-28
NO944001D0 (no) 1994-10-21
AU671830B2 (en) 1996-09-12
CZ261494A3 (en) 1995-02-15
SE9201299D0 (sv) 1992-04-24
NO944001L (no) 1994-10-21
HU219342B (en) 2001-03-28
IL105403A (en) 1998-03-10
RU94045950A (ru) 1996-11-10
DE69305335T2 (de) 1997-04-30
WO1993021907A1 (en) 1993-11-11
JP3536106B2 (ja) 2004-06-07
EP0637236B1 (en) 1996-10-09
ES2094539T3 (es) 1997-01-16
FI110667B (fi) 2003-03-14
DE637236T1 (de) 1995-07-06
IL105403A0 (en) 1993-08-18
US5525354A (en) 1996-06-11
RU2116074C1 (ru) 1998-07-27
HU9403067D0 (en) 1994-12-28
FI944961A0 (fi) 1994-10-21
FI944961L (fi) 1994-10-21

Similar Documents

Publication Publication Date Title
DK0637236T3 (da) Farmaceutisk præparat og fremgangsmåde til dets fremstilling
SE9202250D0 (sv) Controlled release morphine preparation
ATE151285T1 (de) Orale arzneimittel mit kolonspezifischer freisetzung
ES2062417T3 (es) Composiciones farmaceuticas de cimetidina.
FI973733A0 (fi) Farmaceutiskt preparat och foerfarande foer dess framstaellning
IS4146A (is) Lyfjablanda til að gefa dýrum um munn sem inniheldur prótonupumpublokkara
AR042345A2 (es) Un procedimiento para la preparacion de una composicion farmaceutica para el tratamiento de aterosclerosis que contiene 8.9 - dehidroesterona o sus sales de la misma
CA2125662A1 (en) Transdermally administered system containing acetylsalicylic acid for thrombosis therapy and cancer prophylaxis
SE9700885D0 (sv) New pharmaceutical formulation
ATE321538T1 (de) Orale darreichungsform für pyridin-2- ylmethylsulfinyl-1h-benzimidazole
IT1285079B1 (it) Sistema attuatore per la compensazione dell'allineamento di una macchina.
DK412788D0 (da) Farmaceutisk middel til brug ved behandling af uraemi
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
DK0742716T3 (da) Farmaceutisk sammensætning til systemisk transdermal indgivelse med det aktive middel morphin-6-glucuronid
CA2057456A1 (en) Anti depression pharmaceutical
ITPN920071A0 (it) Sistema di bloccaggio dell'orientamento a 360° del moncone preangolato per implantologia orale.
IT1258818B (it) Composizioni farmaceutiche orali a base di n5-metiltetraidrofolato di calcio
IS4288A (is) 2,4-dísúlfónýlfenýlbútýlnítrón, sölt þess, lyfjablanda ásamt notkun á þessu efnasambandi við framleiðslu á lyfi